Bristol Myers Squibb Return on Investment 2010-2022 | BMY

Current and historical return on investment (ROI) values for Bristol Myers Squibb (BMY) over the last 10 years.
Bristol Myers Squibb ROI - Return on Investment Historical Data
Date TTM Net Income LT Investments & Debt Return on Investment
2022-03-31 $7.26B $69.10B 9.64%
2021-12-31 $8.10B $75.61B 10.31%
2021-09-30 $-4.21B $76.96B -5.19%
2021-06-30 $-4.11B $79.38B -4.85%
2021-03-31 $-4.04B $82.18B -4.60%
2020-12-31 $-6.87B $86.22B -7.60%
2020-09-30 $3.45B $91.59B 3.73%
2020-06-30 $2.54B $91.01B 3.17%
2020-03-31 $2.69B $92.82B 3.98%
2019-12-31 $4.98B $95.09B 10.01%
2019-09-30 $6.61B $42.14B 21.41%
2019-06-30 $7.43B $40.58B 29.49%
2019-03-31 $6.17B $20.95B 31.53%
2018-12-31 $5.97B $19.77B 31.42%
2018-09-30 $5.16B $19.44B 27.51%
2018-06-30 $4.18B $18.09B 21.56%
2018-03-31 $4.96B $18.68B 24.43%
2017-12-31 $5.13B $18.82B 24.37%
2017-09-30 $5.52B $21.90B 25.24%
2017-06-30 $5.90B $21.73B 27.05%
2017-03-31 $6.22B $21.77B 28.54%
2016-12-31 $5.92B $22.06B 27.36%
2016-09-30 $4.42B $21.62B 20.70%
2016-06-30 $3.85B $21.66B 17.96%
2016-03-31 $2.28B $21.14B 10.63%
2015-12-31 $2.08B $20.97B 9.48%
2015-09-30 $2.43B $21.91B 10.93%
2015-06-30 $2.45B $21.91B 10.95%
2015-03-31 $2.84B $22.82B 12.60%
2014-12-31 $2.38B $22.23B 10.54%
2014-09-30 $3.31B $22.47B 14.50%
2014-06-30 $3.12B $22.75B 13.85%
2014-03-31 $3.20B $22.90B 14.53%
2013-12-31 $2.89B $23.22B 13.53%
2013-09-30 $2.54B $21.25B 12.29%
2013-06-30 $2.29B $20.82B 11.20%
2013-03-31 $2.82B $20.22B 13.75%
2012-12-31 $4.17B $20.21B 20.04%
2012-09-30 $5.37B $20.51B 25.50%
2012-06-30 $6.57B $21.02B 30.68%
2012-03-31 $7.28B $21.52B 33.81%
2011-12-31 $6.98B $21.24B 32.56%
2011-09-30 $6.86B $21.87B 32.08%
2011-06-30 $6.67B $21.48B 31.04%
2011-03-31 $6.43B $21.18B 29.82%
2010-12-31 $6.07B $20.97B 28.09%
2010-09-30 $5.73B $22.34B 26.53%
2010-06-30 $5.63B $21.82B 26.56%
2010-03-31 $5.51B $21.31B 26.55%
2009-12-31 $5.32B $20.92B 26.15%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $163.597B $46.385B
Bristol-Myers Squibb is a one of the leading global specialty biopharmaceutical companies focused on the development of treatments targeting serious diseases like cancer, inflammatory, immunologic, cardiovascular or fibrotic diseases. Backed by its blockbuster immuno-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, comprising other drugs like Revlimid, Pomalyst, Sprycel, Yervoy and Empliciti. It also has important immunology and cardiovascular drugs like Orencia and Eliquis. It's experiencing growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program. After the sale of the global Diabetes business to AstraZeneca and the discontinuation of discovery research efforts in virology, it's focusing solely on research in core therapeutic areas like oncology, immuno-oncology, immunoscience, cardiovascular, fibrosis and genetically defined diseases. It acquried Celgene Corporation and MyoKardia. It received regulatory approvals for Reblozyl and Inrebic.
Stock Name Country Market Cap PE Ratio
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00